Hypertriglyceridemia - Pipeline Review, H1 2016

  • ID: 3775397
  • Drug Pipelines
  • 106 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Acasti Pharma Inc.
  • Allergan Plc
  • AstraZeneca Plc
  • BASF SE
  • Pharmena SA
  • Sancilio & Company, Inc.
  • MORE
Hypertriglyceridemia - Pipeline Review, H1 2016

Summary

‘Hypertriglyceridemia - Pipeline Review, H1 2016’, provides an overview of the Hypertriglyceridemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypertriglyceridemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypertriglyceridemia and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hypertriglyceridemia
- The report reviews pipeline therapeutics for Hypertriglyceridemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hypertriglyceridemia therapeutics and enlists all their major and minor projects
- The report assesses Hypertriglyceridemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hypertriglyceridemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hypertriglyceridemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hypertriglyceridemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Acasti Pharma Inc.
  • Allergan Plc
  • AstraZeneca Plc
  • BASF SE
  • Pharmena SA
  • Sancilio & Company, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Hypertriglyceridemia Overview

Therapeutics Development

Pipeline Products for Hypertriglyceridemia - Overview

Hypertriglyceridemia - Therapeutics under Development by Companies

Hypertriglyceridemia - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Hypertriglyceridemia - Products under Development by Companies

Hypertriglyceridemia - Companies Involved in Therapeutics Development

Acasti Pharma Inc.

Allergan Plc

Alnylam Pharmaceuticals, Inc.

Arisaph Pharmaceuticals, Inc.

AstraZeneca Plc

BASF SE

Cardax Pharmaceuticals, Inc.

Catabasis Pharmaceuticals, Inc.

CymaBay Therapeutics, Inc.

Jeil Pharmaceutical Co., Ltd.

Kyorin Pharmaceutical Co., Ltd.

Matinas BioPharma Holdings, Inc.

Pharmena SA

Sancilio & Company, Inc.

Thetis Pharmaceuticals LLC

Zydus Cadila Healthcare Limited

Hypertriglyceridemia - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AEM-28 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AEM-2814 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALN-AC3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALN-ANG - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARI-3037MO - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bezafibrate ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BioE-1115 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAT-2000 Series - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAT-2003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDX-085 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gemcabene calcium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

icosabutate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISIS-APOCIIILRx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MAT-9001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MBX-8025 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MN-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NKPL-66 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omega-3-carboxylic acids - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

saroglitazar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Hypertriglyceridaemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Dyslipidemia and Hypertriglyceridemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRIA-662 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

volanesorsen sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hypertriglyceridemia - Dormant Projects

Hypertriglyceridemia - Discontinued Products

Hypertriglyceridemia - Product Development Milestones

Featured News & Press Releases

May 16, 2016: Akcea Therapeutics Announces Completion of Enrollment in Phase 3 COMPASS Trial of Volanesorsen

Mar 23, 2016: MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia

Feb 24, 2016: SPCI Announces US PTO Allowance of Patent Claims

Nov 18, 2015: Zydus announces clinical trials of Saroglitazar in patients with Severe Hypertriglyceridemia in USA

Jul 29, 2015: Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine

May 25, 2015: Phase 2a Clinical Study of Icosabutate in Patients with Severe Hypertriglyceridemia

Apr 22, 2015: CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia

Mar 02, 2015: Acasti Receives Full Data for Phase II TRIFECTA Trial

Sep 30, 2014: Acasti Announces Positive Top-Line Pharmacokinetic Results

Sep 29, 2014: Acasti Reports Successful CaPre Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C

Sep 02, 2014: Isis Pharmaceuticals Presents Data On ISIS-APOCIIIRX At European Society of Cardiology Congress 2014

Jul 24, 2014: Acasti Announces Oral Presentation on COLT Study Results at 19th World Congress on Heart Disease in Boston

May 06, 2014: FDA Approves EPANOVA for the Treatment of Adults with Severe Hypertriglyceridemia

Mar 31, 2014: Catabasis to Present CAT-2003 Data at the American College of Cardiology’s 63rd Annual Scientific Session

Dec 05, 2013: Catabasis Initiates Phase 2 Trial of CAT-2003 in Patients with Severe Hypertriglyceridemia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Hypertriglyceridemia, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Hypertriglyceridemia - Pipeline by Acasti Pharma Inc., H1 2016

Hypertriglyceridemia - Pipeline by Allergan Plc, H1 2016

Hypertriglyceridemia - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016

Hypertriglyceridemia - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2016

Hypertriglyceridemia - Pipeline by AstraZeneca Plc, H1 2016

Hypertriglyceridemia - Pipeline by BASF SE, H1 2016

Hypertriglyceridemia - Pipeline by Cardax Pharmaceuticals, Inc., H1 2016

Hypertriglyceridemia - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2016

Hypertriglyceridemia - Pipeline by CymaBay Therapeutics, Inc., H1 2016

Hypertriglyceridemia - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016

Hypertriglyceridemia - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016

Hypertriglyceridemia - Pipeline by Matinas BioPharma Holdings, Inc. , H1 2016

Hypertriglyceridemia - Pipeline by Pharmena SA, H1 2016

Hypertriglyceridemia - Pipeline by Sancilio & Company, Inc., H1 2016

Hypertriglyceridemia - Pipeline by Thetis Pharmaceuticals LLC, H1 2016

Hypertriglyceridemia - Pipeline by Zydus Cadila Healthcare Limited, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Hypertriglyceridemia - Dormant Projects, H1 2016

Hypertriglyceridemia - Dormant Projects (Contd..1), H1 2016

Hypertriglyceridemia - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Hypertriglyceridemia, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Acasti Pharma Inc.
  • Allergan Plc
  • AstraZeneca Plc
  • BASF SE
  • Pharmena SA
  • Sancilio & Company, Inc.
  • MORE
According to our recently published report 'Hypertriglyceridemia – Pipeline Review, H1 2016'; Hypertriglyceridemia pipeline therapeutics constitutes close to 25 molecules. which approximately 25 molecules are developed by Companies.

Furthermore, the publisher says; Hypertriglyceridemia Hypertriglyceridemia is a condition in which triglyceride levels are elevated. Causes include diabetes mellitus, obesity, family history and sedentary habits. Symptoms include gastrointestinal pain, difficulty breathing, memory loss, dementia, xanthelasmas and corneal arcus. Treatment includes diuretics, beta-blockers, estrogen therapy and corticosteroids.

The report 'Hypertriglyceridemia – Pipeline Review, H1 2016' outlays comprehensive information on the therapeutics under development for Hypertriglyceridemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Hypertriglyceridemia and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 8, 2, 2, 9 and 1 respectively.
Note: Product cover images may vary from those shown
5 of 6
Acasti Pharma Inc.
Allergan Plc
Alnylam Pharmaceuticals, Inc.
Arisaph Pharmaceuticals, Inc.
AstraZeneca Plc
BASF SE
Cardax Pharmaceuticals, Inc.
Catabasis Pharmaceuticals, Inc.
CymaBay Therapeutics, Inc.
Jeil Pharmaceutical Co., Ltd.
Kyorin Pharmaceutical Co., Ltd.
Matinas BioPharma Holdings, Inc.
Pharmena SA
Sancilio & Company, Inc.
Thetis Pharmaceuticals LLC
Zydus Cadila Healthcare Limited
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll